文献速递肿瘤 PET/CT骨显像与常规 SPECT

食管癌新辅助放化疗后DW-MRI与FDG-PET/CT评估临床缓解的比较

Clinical response assessment on DW-MRI compared with FDG-PET/CT after neoadjuvant chemoradiotherapy in patients with oesophageal cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-06-22

研究前瞻性纳入33例接受新辅助放化疗及食管切除术的食管癌患者,比较DW-MRI与FDG-PET/CT在放化疗后6至8周检测残留病灶的表现。结果显示MRI检测残留肿瘤的AUC高于FDG-PET/CT,作者认为MRI诊断准确性更高。

要点

  • 33例中7例(21%)达到病理完全缓解。
  • 检测残留肿瘤(ypT+)的AUC:DW-MRI为0.71/0.70,FDG-PET/CT为0.54/0.57。
  • 检测任何残留病灶的AUC:MRI为0.74/0.70,FDG-PET/CT为0.49/0.60。

核心结论

  • 在新辅助放化疗后6至8周,MRI检测食管癌残留肿瘤的诊断准确性高于FDG-PET/CT。

研究设计与样本

  • 前瞻性纳入接受新辅助放化疗及食管切除术的食管癌患者,共33例。
  • 所有患者在新辅助放化疗前及放化疗后6至8周接受FDG-PET/CT和MRI检查。
  • 由两名放射科医生评分MRI、两名核医学科医生评分FDG-PET/CT,均采用5分法评估残留病灶;以食管切除术后组织病理学为参考标准。

主要发现

  • 33例中7例(21%)达到病理完全缓解。
  • 检测残留肿瘤(ypT+)的AUC:DW-MRI为0.71/0.70,FDG-PET/CT为0.54/0.57。
  • 检测残留淋巴结病灶(ypN+)的AUC:DW-MRI为0.89/0.81,FDG-PET/CT为0.75/0.71。
  • 检测任何残留病灶的AUC/灵敏度/特异度:MRI为0.74/92%/57%和0.70/96%/43%;FDG-PET/CT为0.49/69%/29%和0.60/69%/43%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In about 30% of patients treated with neoadjuvant chemoradiotherapy (nCRT) followed by surgical resection for locally advanced oesophageal cancer no vital tumour is found in the resection specimen. Accurate clinical response assessment is critical if deferral from surgery is considered in complete responders. Our study aimed to compare the performance of MRI and of FDG-PET/CT for the detection of residual disease after nCRT. METHODS: Patients with oesophageal cancer eligible for nCRT and oesophagectomy were prospectively included. All patients underwent FDG-PET/CT and MRI before and between 6 and 8 weeks after nCRT. Two radiologists scored the MRI scans, and two nuclear medicine physicians scored the FDG-PET/CT scans using a 5-point score for residual disease. Histopathology after oesophagectomy represented the reference standard. Sensitivity, specificity, and area under the receiver operating characteristic curve (AUC) were calculated for detection of residual tumour (ypT+), residual nodal disease (ypN+), and any residual disease (ypT+Nx/ypT0N+). RESULTS: Seven out of 33 (21%) patients had a pathological complete response. The AUCs for individual readers to detect ypT+ were 0.71/0.70 on diffusion-weighted (DW)-MRI and 0.54/0.57 on FDG-PET/CT, and to detect ypN+ were 0.89/0.81 on DW-MRI and 0.75/0.71 on FDG-PET/CT. The AUCs/sensitivities/specificities for the individual readers to detect any residual disease were 0.74/92%/57% and 0.70/96%/43% on MRI; these were 0.49/69%/29% and 0.60/69%/43% on FDG-PET/CT, respectively. CONCLUSION: MRI reached higher diagnostic accuracies than FDG-PET/CT for the detection of residual tumour in oesophageal cancer patients at 6 to 8 weeks after nCRT.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Vollenbrock SE, Voncken FEM, Lambregts DMJ, et al. Clinical response assessment on DW-MRI compared with FDG-PET/CT after neoadjuvant chemoradiotherapy in patients with oesophageal cancer. Eur J Nucl Med Mol Imaging. 2020. PMID: 32572560. doi:10.1007/s00259-020-04917-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。